RHEUMATOLOGY INFUSION REFERRAL FORM



PATIENT INFORMATION

Last Name	First Name		DOB
Gender	Last 4 SSN		Primary Language
Address			
City		State	ZIP
Email			
Home Phone	Work Phone		Cell Phone
Primary Contact Method (check one)	☐ Cell Phone ☐ Text ☐ Em ☐ DO NOT CO		ne □Work Phone y Caregiver
Primary Caregiver/Alt Contact	t Name (If applic	cable)	
Caregiver/Alt Contact Email		Careg	iver/Alt Contact Phone

PRESCRIBER INFORMATION

Name of Contact Sending Referral		Title
Preferred Contact ☐ Email Method (check one) ☐ Phone ☐ Fax	Referral Conta	ict Email
Office Phone	Office Fax	
Practice / Facility Name		
Address		
City	State	ZIP
Prescriber Name / Specialty		
Prescriber State License #		DEA#
NPI#		Medicaid UPIN #

INSURANCE INFORMATION

Insurance Provider		Plan ID #
BIN#:	PCN#:	RX Group#:
Insured's Name		Relationship to Patient

Eligible for Medicare (check one)	□ Yes □ No	If yes, list Medicare #	
Prescription Card (check one)	□ Yes □ No	If yes, list carrier	

Please include a copy of the front and back of insurance card

CLINICAL INFORMATION

Prescription Type	☐ Naïve/New Start ☐ Therapy Restart ☐ Existing Treatment	Therapy Start Date
Sample/Starter Product Provided? □Yes □No	If yes, Provide Qty	Date Sample Provided
Allergies □ NKDA □ Drug Allergies (_I	please list)	
Therapies Tried and Failed (pl	ease list medications)	
Concurrent Medications		

Patient He	eight (cm/in)	Patient Weight (kg/lbs)	Date Obtained
Ship to Ac		ne □ Prescriber's Office er (please list)	
ICD-10 Codes	☐ M32.9 Other for ☐ M32.10 Systemic ☐ M32.19 Other or ☐ M05.79 Rheuma ☐ organ or system ☐ M05.89 Other rh	neumatoid arthritis with rheum pecified rheumatoid arthritis, m	atosus, unspecified or system involvement systemic lupis erythematosus factor of multiple sites w/o natoid factor of multiple sites

PRESCRIPTIONS

Patient Last Name	Patient First Name	DOB

PRESCRIPTION INFORMATION

MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
□Benlysta	□IV	□ 10 mg/kg	Starting Dose □ 10 mg/kg IV at week 0, 2, 4 and then every weeks Maintenance Dose □ 10 mg/kg IV everyweeks	□1 month □3 months	□1 year
□Cimzia	□IV	□ 200 mg prefilled syringe □ 200 mg lyophilized powder vial	Starting Dose □ 400 mg (given as two 200 mg subcutaneous injections) at weeks 0,2 and 4 Maintenance Dose □ 200 mg subcutaneous injection every other week □ Other	□1 month □3 months	□1 year
☐ Orencia (abatacept)	□IV	□500 mg Orencia □750 mg Orencia □1000 mg Orencia	□ Infuse over 30 minutes	□ 1 month □ 3 months	□ 1 year
□ Remicade (infliximab)	□IV	Starting Dose 5 mg/kgmg IV at week 0,2,6 3 mg/kgmg IV at week 0,2,6 Other Maintenance Dose 2 mg/kgmg IV every 8 weeks Other	□To be infused over a period NOT less than 2 hours	□ 1 month □ 3 months □	□ 1 year
□Rituxin	□IV	□ 1000 mg IV on day 0, day 14 and then repeat the course everyweeks □ 375 mg/m2 IV every 4 weeks □ Other	□ Infuse as directed	□ 1 month □ 3 months	□1 year
□Simponi Aria (golimumab)	□IV	Starting dose 2 mg/kgmg IV at week 0, 4 and every 8 weeks Other Maintenance Dose 2 mg/kgmg IV every 8 weeks Other	□ Infuse diluted solution over a period of 30 minutes	□1 month □3 months	□ 1 year □

See next page for additional medications.

Patient Signature		
ratient signature	Date	Account Manager
	//	

**The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

PRESCRIPTIONS

Prescriber Signature

Supervising Physician Signature (Dispense as Written)

		Pa	atient First Name	DOB	
PRESCRIPTION	I INFOF	RMATION			
EDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
Normal Saline D5W	□IV	□3 mL □5 mL □	☐ Before and after infusion ☐	□1 month □3 months	□1 year
Heparin 10 units/mL Heparin 100 units/mL	□IV	□3 mL □5 mL	☐ After infusion ☐	□1 month □3 months	□1 year
Diphenhydramine	□PO □IV □IM	□ 25 mg □ 50 mg	☐ After infusion ☐ PRN Allergic Reaction: ☐	□With each infusion	□1 year
Acetaminophen	□РО	□ 325 mg □ 500 mg □ 650 mg □ 1 gm □	□ Pre-Med:	□ With each	□1 year
] Epinephrine	□IM □SQ	☐ Adult 1:1000, 0.3 mL (>30kg/>66lbs) ☐ Peds 1:2000, 0.3 mL (15-30kg/33-66lbs)	□ PRN Anaphylaxis □ Repeating Dose:	□ Once	□1 year
Other:					
Vascular Access Method	□periphe	ral □central □other:			
lled nursing visits as need			and assess general status and response to therapy. E		
edles, syringes, ancillary s eedle, syringes, etc). If ship	upplies and r oped to physi	nedical equipment necessary to establish cian's office, physician accepts on behalf	access and administer medication. Prescription to i	include all necessary ancillary supplie	

**The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.

Date

Date

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.